Skip to main content
ROCKET PHARMACEUTICALS, INC. logo

ROCKET PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · RCKT ISIN · US77313F1066 LEI · 549300R7VV82YUIN4Y93 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2015-01-22 Capital/Financing Update
Country US United States of America
Listing US RCKT

About ROCKET PHARMACEUTICALS, INC.

https://www.rocketpharma.com/

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company that develops gene therapies for rare and devastating diseases. The company's mission is to provide cures by correcting the root cause of disease at the genetic level. It utilizes a multi-platform approach, employing both ex vivo lentiviral (LV) and in vivo adeno-associated viral (AAV) technologies. This strategy allows for the selection of the most suitable platform for specific conditions, with a focus on diseases with high unmet needs, including bone marrow-derived and cardiovascular disorders. Rocket aims to advance a sustainable pipeline of first-in-class investigational genetic therapies for patients.

Recent filings

Filing Released Lang Actions
AMENDMENT NO.3 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 3 to Form S-1 filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes detailed information about an initial public offering (IPO) of common stock and concurrent offering of convertible senior notes. The document contains a prospectus with sections such as Risk Factors, Use of Proceeds, Capitalization, Management's Discussion and Analysis, Business, Management, Executive Compensation, and Financial Statements. This type of filing is used to register securities for public offering and is not a financial report like an annual or quarterly report, nor is it an earnings release or a proxy statement. It is a capital markets filing related to fundraising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or certification, supporting a high confidence level.
2015-01-22 English
AMENDMENT NO.2 TO FORM S-1
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 2 to Form S-1 Registration Statement filed with the SEC. Form S-1 is used for initial public offerings and registration of securities under the Securities Act of 1933. The text includes detailed information about the securities being registered, offering price, underwriting, and other related disclosures typical of a registration statement prospectus. It is not an annual report, earnings release, or any other type of financial report. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the filing itself, not just an announcement or notice.
2015-01-14 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from a company and its legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1. It discusses specific SEC comments and the company's responses related to financial disclosures and valuation assumptions in the registration statement. The document is not a financial report itself but a regulatory correspondence addressing SEC review comments. It is short (4019 characters) and serves as a regulatory filing rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2014-11-27 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Inotek Pharmaceuticals Corporation to the SEC regarding a confidential treatment request related to their Registration Statement on Form S-1 filed for an IPO. It discusses valuation methodologies, estimated price ranges, and probability-weighted scenarios for the IPO and other liquidity events. The document is a supplemental response to SEC comments and requests confidential treatment for sensitive information. It is not a financial report, earnings release, or management discussion but rather a regulatory correspondence related to a registration statement and confidential treatment request. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory communication and does not contain financial statements or report data itself.
2014-11-27 English
Regulatory Filings 2014
Regulatory Filings
2014-11-26 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Inotek Pharmaceuticals Corporation to the SEC requesting confidential treatment for certain information related to their Registration Statement on Form S-1 filed for an IPO. It discusses valuation methodologies, estimated offering price range, and other IPO-related details. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory correspondence related to an IPO registration statement. It is not a report publication announcement since it contains substantive content and is not merely announcing a report. It is not a certification letter either, but a detailed confidential treatment request letter. The document fits best under Regulatory Filings (RNS) as it is a regulatory correspondence that does not fit other specific categories.
2014-11-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.